02.02.2013 Views

MARKS PUBLISHED FOR OPPOSITION - U.S. Patent and ...

MARKS PUBLISHED FOR OPPOSITION - U.S. Patent and ...

MARKS PUBLISHED FOR OPPOSITION - U.S. Patent and ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

JUNE 26, 2012 U.S. PATENT AND TRADEMARK OFFICE TM 455<br />

CLASS 5—(Continued).<br />

SN 85-533,081. BIOTEST PHARMACEUTICALS CORPORA-<br />

TION, BOCA RATON, FL. FILED 2-3-2012.<br />

THE MARK CONSISTS OF STANDARD CHARACTERS<br />

WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,<br />

SIZE, OR COLOR.<br />

<strong>FOR</strong> IMMUNE GLOBULIN <strong>FOR</strong> TREATMENT OF<br />

PRIMARY IMMUNODEFICIENCY DISEASE (U.S. CLS.<br />

6, 18, 44, 46, 51 AND 52).<br />

AMY C. KEAN, EXAMINING ATTORNEY<br />

SN 85-533,212. NOVARTIS AG, BASEL, SWITZERLAND,<br />

FILED 2-3-2012.<br />

THE MARK CONSISTS OF STANDARD CHARACTERS<br />

WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,<br />

SIZE, OR COLOR.<br />

<strong>FOR</strong> ANTI-INFLAMMATORIES; ANTIBACTERIAL<br />

PHARMACEUTICALS; ANTIBIOTICS; ANTIFUNGAL<br />

PREPARATIONS; ANTIVIRALS; CARDIOVASCULAR<br />

PHARMACEUTICALS; PHARMACEUTICAL PREPARA-<br />

TIONS ACTING ON THE CENTRAL NERVOUS SYSTEM;<br />

PHARMACEUTICAL PREPARATIONS AND SUB-<br />

STANCES <strong>FOR</strong> THE TREATMENT OF GASTRO-INTEST-<br />

INAL DISEASES; PHARMACEUTICAL PREPARATIONS<br />

<strong>FOR</strong> THE TREATMENT AND PREVENTION OF DIS-<br />

EASES AND DISORDERS OF THE AUTOIMMUNE<br />

SYSTEM, THE METABOLIC SYSTEM, THE MUSCULO-<br />

SKELETAL SYSTEM AND THE GENITOURINARY SYS-<br />

TEM; PHARMACEUTICAL PREPARATIONS <strong>FOR</strong> USE<br />

IN HEMATOLOGY AND IN TISSUE AND ORGAN<br />

TRANSPLANTATION; PHARMACEUTICAL PREPARA-<br />

TIONS <strong>FOR</strong> THE TREATMENT OF EYE DISEASES AND<br />

CONDITIONS; PHARMACEUTICAL PREPARATIONS<br />

<strong>FOR</strong> THE TREATMENT OF HEART RHYTHM DISOR-<br />

DERS; PHARMACEUTICAL PREPARATIONS <strong>FOR</strong> THE<br />

TREATMENT OF IMMUNE SYSTEM RELATED DIS-<br />

EASES AND DISORDERS; PHARMACEUTICAL PRE-<br />

PARATIONS <strong>FOR</strong> THE TREATMENT OF KIDNEY<br />

DISEASES; PHARMACEUTICAL PREPARATIONS <strong>FOR</strong><br />

TREATING DIABETES; PHARMACEUTICAL PREPARA-<br />

TIONS <strong>FOR</strong> USE IN DERMATOLOGY; PHARMACEUTI-<br />

CAL PRODUCTS <strong>FOR</strong> OPHTHALMOLOGICAL USE;<br />

PHARMACEUTICAL PRODUCTS <strong>FOR</strong> THE PREVEN-<br />

TION AND TREATMENT OF CANCER; PHARMACEU-<br />

TICAL PRODUCTS <strong>FOR</strong> THE TREATMENT OF BONE<br />

DISEASES; PHARMACEUTICAL PRODUCTS <strong>FOR</strong><br />

TREATING RESPIRATORY DISEASES; PHARMACEU-<br />

TICAL PRODUCTS <strong>FOR</strong> TREATING RESPIRATORY<br />

DISEASES AND ASTHMA; PHARMACEUTICALS,<br />

NAMELY, ANTI-INFECTIVES (U.S. CLS. 6, 18, 44, 46, 51<br />

AND 52).<br />

GEORGE LORENZO, EXAMINING ATTORNEY<br />

CLASS 5—(Continued).<br />

SN 85-533,213. NOVARTIS AG, BASEL, SWITZERLAND,<br />

FILED 2-3-2012.<br />

THE MARK CONSISTS OF STANDARD CHARACTERS<br />

WITHOUT CLAIM TO ANY PARTICULAR FONT, STYLE,<br />

SIZE, OR COLOR.<br />

<strong>FOR</strong> ANTI-INFLAMMATORIES; ANTIBACTERIAL<br />

PHARMACEUTICALS; ANTIBIOTICS; ANTIFUNGAL<br />

PREPARATIONS; ANTIVIRALS; CARDIOVASCULAR<br />

PHARMACEUTICALS; PHARMACEUTICAL PREPARA-<br />

TIONS ACTING ON THE CENTRAL NERVOUS SYSTEM;<br />

PHARMACEUTICAL PREPARATIONS AND SUB-<br />

STANCES <strong>FOR</strong> THE TREATMENT OF GASTRO-INTEST-<br />

INAL DISEASES; PHARMACEUTICAL PREPARATIONS<br />

<strong>FOR</strong> THE TREATMENT AND PREVENTION OF DIS-<br />

EASES AND DISORDERS OF THE AUTOIMMUNE<br />

SYSTEM, THE METABOLIC SYSTEM, THE MUSCULO-<br />

SKELETAL SYSTEM AND THE GENITOURINARY SYS-<br />

TEM; PHARMACEUTICAL PREPARATIONS <strong>FOR</strong> USE<br />

IN HEMATOLOGY AND IN TISSUE AND ORGAN<br />

TRANSPLANTATION; PHARMACEUTICAL PREPARA-<br />

TIONS <strong>FOR</strong> THE TREATMENT OF EYE DISEASES AND<br />

CONDITIONS; PHARMACEUTICAL PREPARATIONS<br />

<strong>FOR</strong> THE TREATMENT OF HEART RHYTHM DISOR-<br />

DERS; PHARMACEUTICAL PREPARATIONS <strong>FOR</strong> THE<br />

TREATMENT OF IMMUNE SYSTEM RELATED DIS-<br />

EASES AND DISORDERS; PHARMACEUTICAL PRE-<br />

PARATIONS <strong>FOR</strong> THE TREATMENT OF KIDNEY<br />

DISEASES; PHARMACEUTICAL PREPARATIONS <strong>FOR</strong><br />

TREATING DIABETES; PHARMACEUTICAL PREPARA-<br />

TIONS <strong>FOR</strong> USE IN DERMATOLOGY; PHARMACEUTI-<br />

CAL PRODUCTS <strong>FOR</strong> OPHTHALMOLOGICAL USE;<br />

PHARMACEUTICAL PRODUCTS <strong>FOR</strong> THE PREVEN-<br />

TION AND TREATMENT OF CANCER; PHARMACEU-<br />

TICAL PRODUCTS <strong>FOR</strong> THE TREATMENT OF BONE<br />

DISEASES; PHARMACEUTICAL PRODUCTS <strong>FOR</strong><br />

TREATING RESPIRATORY DISEASES; PHARMACEU-<br />

TICAL PRODUCTS <strong>FOR</strong> TREATING RESPIRATORY<br />

DISEASES AND ASTHMA; PHARMACEUTICALS,<br />

NAMELY, ANTI-INFECTIVES (U.S. CLS. 6, 18, 44, 46, 51<br />

AND 52).<br />

GEORGE LORENZO, EXAMINING ATTORNEY

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!